Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. H.W. (Hans) Nijman

Publicaties

Is it time to abandon staging surgery and prolonged follow-up in patients with primary adult-type granulosa cell tumor?

Retinoblastoma Protein Loss in p53 Abnormal Endometrial Carcinoma: Histologic and Clinicopathological Correlates

Vvax001, a Therapeutic Vaccine for Patients with HPV16-positive High-grade Cervical Intraepithelial Neoplasia: a Phase II Trial

APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma-a multicenter, single-arm, phase II, clinical proof-of-concept study

B cells critical for outcome in high grade serous ovarian carcinoma

Correction to: Prediction of recurrence risk in endometrial cancer with multimodal deep learning (Nature Medicine, (2024), 10.1038/s41591-024-02993-w)

Diagnostic accuracy of MRI, CT, and [18F]FDG-PET-CT in detecting lymph node metastases in clinically early-stage cervical cancer — a nationwide Dutch cohort study

Genomic instability as a driver and suppressor of anti-tumor immunity

ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.

Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study

Pers/media

Ziekenhuiskoepel ziet uitwerking concentratieplannen kankerzorg niet zitten

Kankerzorg straks in minder ziekenhuizen: ‘Niet alle zorg kan meer om de hoek'

‘Niemand kan achteroverleunen’

UMCG ontvangt subsidie voor onderzoek naar immuuntherapie bij baarmoederkanker

Hoogleraar UMCG maakt plan kankerzorg voor Zorginstituut Nederland

Oncoloog Hans Nijman is kwartiermaker netwerk- en expertzorg kanker

„Werk aan de winkel met kankerpreventie”

Subsidie voor minder belastende behandeling schaamlipkanker